Prof. Andrew Levy received his BA Summa Cum Laude from Yale University in Molecular Biophysics and Biochemistry in 1982. He received a MSTP scholarship for his MD PHD training (1982-1990) at Johns Hopkins Medical School performing his PHD under Nobel Laureate Daniel Nathans working on the identification of a growth factor now known as Vascular Endothelial Growth Factor. He completed internal medicine residency at Johns Hopkins Hospital (1990-1992) and a cardiovascular fellowship at Brigham and Women’s Hospital at Harvard Medical School (1992-1996).  He is a tenured professor at Technion Faculty of Medicine, Technion Israel Institute of Technology in Haifa, Israel. His current focus of research is on developing treatments for IQSEC2 disease – a neurodevelopmental disorder associated with drug-resistant epilepsy, autism, and severe intellectual disability. Founder of IQSEC2 Research and Advocacy Foundation, a volunteer group of parents working towards providing support for parents, increasing awareness of IQSEC2.